New blood test combined with image-based prostate cancer screening reduces harm and costs
The mechanisms behind cancer cell resistance to TRAIL treatment
28 January 2022Maternity care during COVID-19: Pandemic added new challenges
28 January 2022New blood test combined with image-based prostate cancer screening reduces harm and costs
The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study from Karolinska Institutet published in the journal European Urology. The results provide support for organized prostate cancer testing in Sweden, researchers say.
